IP Library Granted Patent US 7,951,806
Granted Patent B2
US 7,951,806 · App. 12/046,547 · Granted May 31, 2011

Plasminogen activator inhibitor-1 inhibitor

Assignee: Renascience Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,951,806
App. No.
12/046,547
Granted
May 31, 2011
Kind
B2
Abstract

The present invention relates to an inhibitor of plasminogen activator inhibitor-1. The present invention further relates to a pharmaceutical composition that has an inhibitory action on PAI-1 activity and is useful in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity. Furthermore, the present invention relates to a novel compound having PAI-1 inhibitory activity represented by the following general formula (I), and a salt thereof. Each symbol is defined as those in the specification.

Claims (117)

1. A compound represented by formula (I), or a salt or solvate thereof

wherein

—R 1 and R 2 , the same or different, each represent a hydrogen atom, halogen atom, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, cycloalkenyl, alkynyl, hydroxyl, alkoxy, cycloalkoxy, alkenyloxy, cycloalkenyloxy, aryloxy, aralkyl, aralkyloxy, heterocyclic group, heterocyclic-alkyl, or heterocyclic-alkyloxy group; or substituted or unsubstituted aryl group; or amino, carbamoyl, cyano, carboxy or alkoxycarbonyl group that may be substituted or unsubstituted with 1 to 2 substituents; and may adjoin with each other to form a ring;

—R 3 is a hydrogen atom; or substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl or aralkyl group;

—X is a sulfur atom or —C(R 5 )═C(R 6 )—, wherein R 5 and R 6 each represent a hydrogen atom, halogen atom, or substituted or unsubstituted alkyl or alkoxy group;

—B is a carboxy, alkoxycarbonyl, 1H-tetrazol-5-yl, 4,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl, 4,5-dihydro-5-thioxo-4H-1,2,4-oxadiazol-3-yl, or 4,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl group;

-L is substituted or unsubstituted alkylene (some carbon atoms in the alkylene may form a cycloalkyl ring), alkenylene, alkynylene, cycloalkylene, alkyleneoxyalkylene, alkylenethioalkylene, alkylene-SO-alkylene or alkylene-SO 2 -alkylene, or alkylene-N(R 9 )-alkylene group, wherein R 9 is a hydrogen atom, or a substituted or unsubstituted alkyl group;

-n is an integer of 0 or 1;

-A is —COR 10

wherein

R 10 is N(R 14 )(R 15 ), wherein R 14 and R 15 , the same or different, each represent a hydrogen atom, a substituted or unsubstituted alkyl, alkenyl, cycloalkenyl, alkynyl, bicycloalkyl, bicycloalkenyl, adamanthyl, aryl, heterocyclic ring, aralkyl (including diphenylalkyl) or heterocyclic-alkyl group, or R 10 is a group represented by the following formula:

wherein m is an integer of 1 to 4, Y represents a nitrogen atom, CH, C(R 16 ′)—, C(OH)— or CH—O—; R 16 and R 16 ′, the same or different, each represent a hydrogen atom, a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, bicycloalkyl, bicycloalkenyl, adamanthyl, aryl or aralkyl group (including diphenylalkyl); and R 21 and R 21 ′, the same or different, each represent a hydrogen atom, a substituted or unsubstituted alkyl, or phenyl group.

2. The compound according to claim 1 excluding thiophene compounds represented by formula (I′), or a salt thereof:

wherein R 1 ′ and R 1 ″, the same or different, each represent a hydrogen atom, substituted or unsubstituted phenyl or thienyl group, or C 1-6 straight- or branched-chain alkyl group; R 2 ′ and R 2 ″, the same or different, each represent a hydrogen atom, substituted or unsubstituted phenyl group, C 1-6 straight- or branched-chain alkyl group, or a halogen atom; R 1 ′ and R 2 ′, and R 1 ″ and R 2 ″, may join together to form a 5- or 6-membered ring; and L′ represents a C 1-7 straight- or branched-chain alkylene, alkenylene or alkynylene group, or C 3-8 cycloalkylene group.

3. The compound or salt or solvate thereof according to claim 1 , wherein the compound is a thiophen-3-carboxylic acid represented by formula (II), or a bioisoster thereof:

wherein R 1 , R 2 , R 3 , L, B, n and A are defined as in claim 1 .

4. The compound or salt or solvate thereof according to claim 1 , wherein the compound is a benzoic acid represented by formula (III), or a bioisoster thereof:

wherein R 1 , R 2 , R 3 , L, B, n and A are defined as in claim 1 .

5. A compound, or salt or solvate thereof, wherein the compound is selected from the group consisting of compounds (1) to (91):

(1) 2-(6-(3-(tert-butoxycarbonyl)-4-phenylthiophen-2-ylamino)-6-oxo-hexanamido)benzoic acid,

(2) 2-(6-(3-(tert-butoxycarbonyl)-4-phenylthiophen-2-ylamino)-6-oxo-hexanamido)-5-chlorobenzoic acid,

(3) 2-(6-oxo-6-(4-phenylthiophen-2-ylamino)hexanamido)benzoic acid,

(4) 2-(6-(2-carboxy-4-chlorophenylamine)-6-oxo-hexanamido)-4-phenylthiophen-3-carboxylic acid,

(5) 2-(6-oxo-6-(4-phenylpiperidin-1-yl)hexanamido)-4-phenylthiophen-3-carboxylic acid,

(6) 2-(6-(4-chlorophenylamino)-6-oxo-hexanamido)-4-phenylthiophen-3-carboxylic acid,

(7) 2,2′-(oxybis((1-oxo-2,1-ethanediyl)imino))bis(5-methyl-4-phenylthiophen-3-carboxylic acid),

(8) 2,2′-(oxybis((1-oxo-2,1-ethanediyl)imino))bis(5-phenylthiophen-3-carboxylic acid),

(9) 2,2′-(oxybis((1-oxo-2,1-ethanediyl)imino))bis(4-phenylthiophen-3-carboxylic acid),

(10) 2-(2-(2-(3-(tert-butoxycarbonyl)-5-methyl-4-phenylthiophen-2-ylamino)-2-oxoethoxy)acetamido)-5-methyl-4-phenylthiophen-3-carboxylic acid,

(11) 2-(6-(3-(tert-butoxycarbonyl)-4-isopropylthiophen-2-ylamino)-6-oxo-hexanamido)benzoic acid,

(12) 2-(6-(4-isopropylthiophen-2-ylamino)-6-oxo-hexanamido)benzoic acid,

(13) 2-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-5-methyl-4-(pyridin-4-yl)thiophen-3-carboxylic acid,

(14) 2-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-5-methyl-4-(pyridin-3-yl)thiophen-3-carboxylic acid,

(15) 2-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-5-methyl-4-phenylthiophen-3-carboxylic acid,

(16) 2-(2-(benzyloxycarbonylamino)-5-(4-chlorophenylamino)-5-oxopentanamido)-5-chlorobenzoic acid,

(17) 2-(2-(benzyloxycarbonylamino)-5-((4-chlorophenyl)(methyl)amino)-5-oxopentanamido)-5-chlorobenzoic acid,

(18) 2-(2-(benzyloxycarbonylamino)-5-oxo-5-(4-phenylpiperazin-1-yl)pentanamido)-5-chlorobenzoic acid,

(19) 2-(5-(4-benzhydryl piperazin-1-yl)-2-(benzyloxycarbonylamino)-5-oxopentanamido)-5-chlorobenzoic acid,

(20) 2-(5-(4-benzhydryl piperazin-1-yl)-4-(benzyloxycarbonylamino)-5-oxopentanamido)-5-chlorobenzoic acid,

(21) 2-(5-(4-benzhydryl piperazin-1-yl)-2-(tert-butoxycarbonylamino)-5-oxopentanamido)-5-chlorobenzoic acid,

(22) 2-(2-amino-5-(4-benzhydryl piperazin-1-yl)-5-oxopentanamido)-5-chlorobenzoic acid,

(23) 5-chloro-2-(2-((2-(4-chlorophenylamino)-2-oxoethyl)(methyl)amino)acetamido)benzoic acid,

(24) 2-(2-((2-(4-benzhydryl piperazine-1-yl)-2-oxoethyl)(methyl)amino)acetamido)-5-chlorobenzoic acid,

(25) 5-chloro-2-(6-(4-chlorophenylamin)-6-oxo-hexanamido)benzoic acid,

(26) 2-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-5-methoxybenzoic acid,

(27) 5-chloro-2-(2-(2-(4-(4-chlorophenyl)piperazin-1-yl)-2-oxoethoxy)acetamido)benzoic acid,

(28) 2-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-5-chlorobenzoic acid,

(29) 2-(2-(2-(4-benzhydryloxy)piperidin-1-yl)-2-oxoethoxy)acetamido-5-chlorobenzoic acid,

(30) 5-chloro-2-(2-(2-(4,4-diphenylpiperidin-1-yl)-2-oxoethoxy)acetamido)benzoic acid,

(31) 2-(2-(2-(4-chloro-2-(methoxycarbonyl)phenylamino)-2-oxoethoxy)acetamido)-5-methyl-4-phenylthiophen-3-carboxylic acid,

(32) 2-(2-(2-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-2-oxoethoxy)acetamido)-5-chlorobenzoic acid,

(33) 2-(2-(2-(1-adamantylamino)-2-oxoethoxy)acetamido)-5-chlorobenzoic acid,

(34) 2-(2-(2-(4-(9H-fluoren-9-yl)piperazin-1-yl)-2-oxoethoxy)acetamido)-5-chlorobenzoic acid,

(35) 2-(2-(2-(benzhydrylamino)-2-oxoethoxy)acetamido)-5-chlorobenzoic acid,

(36) 2-(2-(2-(3-(tert-butoxycarbonyl)-5-methyl-4-phenylthiophen-2-ylamino)-2-oxoethoxy)acetamido)-5-chlorobenzoic acid,

(37) 5-chloro-2-(2-(2-(4-chlorophenylamino)-2-oxoethoxy)acetamido)benzoic acid,

(38) 2-(2-(2-(2-benzoyl-4-chlorophenylamino)-2-oxoethoxy)acetamido)-5-chlorobenzoic acid,

(39) 2-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-5-fluorobenzoic acid,

(40) 3-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)benzoic acid,

(41) 4-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-3-chlorobenzoic acid,

(42) 4-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-4′-fluorobiphenyl-3-carboxylic acid,

(43) 4-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-2′,4′-difluorobiphenyl-3-carboxylic acid,

(44) 4-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-4′-cyano biphenyl-3-carboxylic acid,

(45) 4-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-4′-(dimethylamino)biphenyl-3-carboxylic acid,

(46) 4-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-4′-methoxybiphenyl-3-carboxylic acid,

(47) 4-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-4′-morpholinobiphenyl-3-carboxylic acid,

(48) 2-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-5-(pyridine-4-yl)benzoic acid,

(49) 2-(2(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-5-bromobenzoic acid,

(50) 2-(2-(2-benzhydrylamino)-2-oxoethoxy)acetamido-5-(pyridine-4-yl)benzoic acid,

(51) 2-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-5-(pyridin-3-yl)benzoic acid,

(52) 2-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-5-(pyridine-4-yl)benzoic acid,

(53) 2-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-5-(1-methyl-1H-pyrazol-4-yl)benzoic acid,

(54) 2-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)-5-benzylbenzoic acid,

(55) 4-(2-(2-(4-benzhydryl piperazin-1-yl)-2-oxoethoxy)acetamido)biphenyl-3-carboxylic acid,

(56) 4-(2-(2-(4-chlorophenylamino)-2-oxoethoxy)acetamido) biphenyl-3-carboxylic acid,

(57) 2,2′-(oxybis((1-oxo-2,1-ethanediyl)imino))bis(5-phenylbenzen-1-carboxylic acid),

(58) 2-(2-(2-(4-benzhydrylpiperazin-1-yl)-2-oxoethoxy)acetamido)-5-isobutyl benzoic acid,

(59) 2-(2-(2-(4-benzhydrylpiperazin-1-yl)-2-oxoethoxy)acetamido)-5-(1H-pirazol-4-yl)benzoic acid,

(60) 2-(2-(2-(4-benzhydrylpiperazin-1-yl)-2-oxoethoxy)acetamido)-5-(quinolin-3-yl)benzoic acid,

(61) 2-(2-(2-(4-benzhydrylpiperazin-1-yl)-2-oxoethoxy)acetamido)-5-(benzo[b]thiophen-2-yl)benzoic acid,

(62) 4-(2-(2-(benzhydrylamino)-2-oxoethoxy)acetamido)-4′-fluorobiphenyl-3-carboxylic acid,

(63) 5-chloro-2-(2-(2-(2,6-diisopropylphenylamino)-2-oxoethoxy)acetamido)benzoic acid,

(64) 5-chloro-2-(2-(2-(1-(naphthalen-1-yl)ethylamino)-2-oxoethoxy)acetamido)benzoic acid,

(65) 5-chloro-2-(2-(2-(5-isopropyl-2-methylphenylamino)-2-oxoethoxy)acetamido)benzoic acid,

(66) 5-chloro-2-(2-(2-oxo-2-(4-phenylbutylamino)ethoxy)acetamido)benzoic acid,

(67) 2-(2-(2-(bis(4-fluorophenyl)methyl)amino-2-oxoethoxy)acetamido)-5-chlorobenzoic acid,

(68) 2-(2-(2-(bis(4-(trifluoromethyl)benzyl)amino)-2-oxoethoxy)acetamido)-5-chlorobenzoic acid,

(69) 2-(2-(2-(bis(4-fluorobenzyl)amino)-2-oxoethoxy)acetamido)-5-chlorobenzoic acid,

(70) 2-(2-(2-(3,5-bis(trifluoromethyl)phenylamino)-2-oxoethoxy)acetamido)-5-chlorobenzoic acid,

(71) 2-(2-(2-(4-benzhydrylpiperazin-1-yl)-2-oxoethoxy)acetamido)-4-chlorobenzoic acid,

(72) 2-(2-(2-(4-benzhydrylpiperazin-1-yl)-2-oxoethoxy)acetamido)-4-bromobenzoic acid,

(73) 2-(2-(2-(4-benzhydrylpiperazin-1-yl)-2-oxoethoxy)acetamido)-4-(pyridin-4-yl)benzoic acid,

(74) 3-(2-(2-(4-benzhydrylpiperazin-1-yl)-2-oxoethoxy)acetamido)-4′-fluorobiphenyl-4-carboxylic acid,

(75) 2-(2-(benzhydrylamino)-2-oxoacetamido)-5-chlorobenzoic acid,

(76) 2-(5-(4-benzhydrylpiperazin-1-yl)-5-oxopentanamido)-5-chlorobenzoic acid,

(77) 2-(2-(2-(4-benzhydrylpiperazin-1-yl)-2-oxoethoxy)acetamido)-5-(2,4-dimethylthiazol-5-yl)benzoic acid,

(78) 2-(2-(2-(benzhydrylamino)-2-oxoethoxy)acetamido)-5-methyl-4-phenylthiophen-3-carboxylic acid,

(79) 5-chloro-2-(2-(2-(diphenylamino)-2-oxoethoxy)acetamido)benzoic acid,

(80) 5-chloro-2-(2-(2-(2,2-diphenylethylamino)-2-oxoethoxy)acetamido)benzoic acid,

(81) 2-(2-(2-((3S*,5R*)-4-benzhydryl-3,5-dimethylpiperazin-1-yl)-2-oxoethoxy)acetamido)-5-chlorobenzoic acid,

(82) 2-(2-(2-(4-benzhydrylpiperazin-1-yl)-2-oxoethoxy)acetamido)-5-(benzyloxy)benzoic acid,

(83) 2-(2-(2-(4-benzhydrylpiperazin-1-yl)-2-oxoethoxy)acetamido)-5-isobutoxybenzoic acid,

(84) 2-(2-(4-benzhydrylpiperazin-1-yl)-2-oxoethoxy)-N-(4-chloro-2-(1H-tetrazol-5-yl)phenyl)acetamide,

(85) 2-(2-(4-benzhydrylpiperazin-1-yl)-2-oxoethoxy)-N-(4-chloro-2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl)acetamide,

(86) 2-(2-(4-benzhydrylpiperazin-1-yl)-2-oxoethoxy)-N-(5-methyl-4-phenyl-3-(1H-tetrazol-5-yl)thiophen-2-yl)acetamide,

(87) 2-(2-((2-(benzhydrylamino)-2-oxoethyl)(methyl)amino)acetamido)-5-chlorobenzoic acid,

(88) 2-(2-(2-(4-benzhydrylpiperazin-1-yl)-2-oxoethylthio)acetamido)-5-chlorobenzoic acid,

(89) 2-(2-(1-(2-(4-benzhydrylpiperazin-1-yl)-2-oxyethyl)cyclohexyl)acetamido)-5-chlorobenzoic acid,

(90) 2-((1S*,2S*)-2-(4-benzhydrylpiperazine-1-carbonyl)cyclohexanecarboxamido)-5-chlorobenzoic acid, and

(91) 2-((1S*,2R*)-2-(4-benzhydrylpiperazine-1-carbonyl)cyclohexanecarboxamido)-5-chlorobenzoic acid.

6. A method for producing an aromatic or heterocyclic carboxylic acid represented by formula (Ic), comprising the following steps (c), (d) and (x):

(c) a step of reacting the compound (1) and an intramolecular anhydride of dicarboxylic acid (5) to form an ester carboxylic acid compound (6a), represented by the formulae below,

(d) a step of reacting the ester carboxylic acid (6a) formed in the above step (c) and a compound (7) to form an ester compound (4c), and

(x) a step of removing the R 17 group from the ester compound (4c) formed in the above step (d) to produce an aromatic or heterocyclic carboxylic acid (Ic);

wherein R 1 , R 2 , R 3 , R 10 , L and X are defined as in claim 1 , and R 17 is alkyl, aryl or aralkyl.

7. A pharmaceutical composition comprising a compound, or a salt or solvate thereof, according to any one of claims 1 to 5 , and a pharmaceutically acceptable carrier or additive.

8. The pharmaceutical composition according to claim 7 , the composition being in a form for oral administration.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED ON REEL 021226 FRAME 0570. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ALL RIGHTS IN U.S. APPLN. NO. 12/046,547 TO RENASCIENCE CO., LTD.. Recorded Jul 28, 2008
From: JR TOKAI PARTNERS CO., LTD.
To: RENASCIENCE CO., LTD.
Reel/Frame 021299/0612 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2008
From: JR TOKAI PARTNERS CO., LTD.
To: RENASCIENCE CO., LTD.
Reel/Frame 021226/0570 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2008
From: MIYATA, TOSHIO; YAMAOKA, NAGAHISA; KODAMA, HIDEHIKO
To: JR TOKAI PARTNERS CO., LTD.
Reel/Frame 020978/0812 →
Continuity (2)
Provisional Application 60951820 · Jul 25, 2007
Related Publication 20090124620A1 · May 14, 2009